Advancements in Genetic and Biochemical Insights: Unraveling the Etiopathogenesis of Neurodegeneration in Parkinson’s Disease

Parkinson’s disease (PD) is the second most prevalent neurodegenerative movement disorder worldwide, which is primarily characterized by motor impairments. Even though multiple hypotheses have been proposed over the decades that explain the pathogenesis of PD, presently, there are no cures or promising preventive therapies for PD. This could be attributed to the intricate pathophysiology of PD and the poorly understood molecular mechanism. To address these challenges comprehensively, a thorough disease model is imperative for a nuanced understanding of PD’s underlying pathogenic mechanisms. This review offers a detailed analysis of the current state of knowledge regarding the molecular mechanisms underlying the pathogenesis of PD, with a particular emphasis on the roles played by gene-based factors in the disease’s development and progression. This study includes an extensive discussion of the proteins and mutations of primary genes that are linked to PD, including α-synuclein, GBA1, LRRK2, VPS35, PINK1, DJ-1, and Parkin. Further, this review explores plausible mechanisms for DAergic neural loss, non-motor and non-dopaminergic pathologies, and the risk factors associated with PD. The present study will encourage the related research fields to understand better and analyze the current status of the biochemical mechanisms of PD, which might contribute to the design and development of efficacious and safe treatment strategies for PD in future endeavors.

[1]  Lanxia Meng,et al.  The yeast prion protein Sup35 initiates α-synuclein pathology in mouse models of Parkinson’s disease , 2023, Science Advances.

[2]  Jongkyun Kang,et al.  Cell autonomous role of leucine-rich repeat kinase in protection of dopaminergic neuron survival , 2023, bioRxiv.

[3]  Ninghui Zhao,et al.  Iron‐inhibited autophagy via transcription factor ZFP27 in Parkinson's disease , 2023, Journal of cellular and molecular medicine.

[4]  Kyu-Sang Park,et al.  PINK1 and Parkin regulate IP3R-mediated ER calcium release , 2023, Nature communications.

[5]  H. Motaln,et al.  The Role of c-Abl Tyrosine Kinase in Brain and Its Pathologies , 2023, Cells.

[6]  S. Mastana,et al.  Targeting calcium homeostasis and impaired inter-organelle crosstalk as a potential therapeutic approach in Parkinson's disease. , 2023, Life sciences.

[7]  N. Hattori,et al.  Different pieces of the same puzzle: a multifaceted perspective on the complex biological basis of Parkinson’s disease , 2023, NPJ Parkinson's disease.

[8]  J. Prasuhn,et al.  Neuroinflammation and Mitochondrial Dysfunction in Parkinson’s Disease: Connecting Neuroimaging with Pathophysiology , 2023, Antioxidants.

[9]  Liyan Hou,et al.  Serum metabolomics analysis revealed metabolic disorders in Parkinson’s disease , 2023, Medicine.

[10]  A. Kakita,et al.  Phosphorylation of α-synuclein at T64 results in distinct oligomers and exerts toxicity in models of Parkinson’s disease , 2023, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Qi Zhou,et al.  The role of the microbiota-gut-brain axis and intestinal microbiome dysregulation in Parkinson’s disease , 2023, Frontiers in Neurology.

[12]  Mohamed Salama,et al.  The Role of an Altered Gut Microbiome in Parkinson’s Disease: A Narrative Review , 2023, Applied Microbiology.

[13]  V. Jain,et al.  An Insight into Cellular and Molecular Mechanisms Underlying the Pathogenesis of Neurodegeneration in Alzheimer’s Disease , 2023, Biomedicines.

[14]  J. Pu,et al.  Nuclear DJ-1 Regulates DNA Damage Repair via the Regulation of PARP1 Activity , 2023, International journal of molecular sciences.

[15]  Jing Zhang,et al.  The cervical lymph node contributes to peripheral inflammation related to Parkinson’s disease , 2023, Journal of Neuroinflammation.

[16]  Jia Meng,et al.  SIRT1/FOXO3-mediated autophagy signaling involved in manganese-induced neuroinflammation in microglia. , 2023, Ecotoxicology and environmental safety.

[17]  Jie Zhou,et al.  Upregulation of mitochondrial calcium uniporter contributes to paraquat-induced neuropathology linked to Parkinson's disease via imbalanced OPA1 processing. , 2023, Journal of hazardous materials.

[18]  A. Kortholt,et al.  LRRK2 Structure-Based Activation Mechanism and Pathogenesis , 2023, Biomolecules.

[19]  Sevim Isik,et al.  Microglia Mediated Neuroinflammation in Parkinson’s Disease , 2023, Cells.

[20]  S. Khoshnam,et al.  Mitochondrial Dysfunction and Parkinson’s Disease: Pathogenesis and Therapeutic Strategies , 2023, Neurochemical Research.

[21]  M. Grothe,et al.  Peripheral Inflammation Is Associated with Dopaminergic Degeneration in Parkinson's Disease , 2023, Movement disorders : official journal of the Movement Disorder Society.

[22]  P. Calabresi,et al.  Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction , 2023, Cell Death & Disease.

[23]  A. Bortolozzi,et al.  The Role of α-Synuclein in the Regulation of Serotonin System: Physiological and Pathological Features , 2023, Biomedicines.

[24]  Li Gu,et al.  α-Synuclein Induced the Occurrence of RBD via Interaction with OX1R and Modulated Its Degradation , 2023, NeuroMolecular Medicine.

[25]  I. Majsterek,et al.  GBA1 Gene Mutations in α-Synucleinopathies—Molecular Mechanisms Underlying Pathology and Their Clinical Significance , 2023, International journal of molecular sciences.

[26]  M. Feany,et al.  α-Synuclein Promotes Neuronal Dysfunction and Death by Disrupting the Binding of Ankyrin to β-Spectrin , 2023, Journal of Neuroscience.

[27]  D. Keszthelyi Targeting the enteric nervous system to treat constipation in Parkinson's disease. , 2023, Gastroenterology.

[28]  A. Koppes,et al.  Aggregation of alpha-synuclein in enteric neurons does not impact function in vitro , 2022, Scientific reports.

[29]  S. Dahbour,et al.  Non-motor manifestation of Parkinson's disease: a cross-sectional study in a teaching hospital in Jordan , 2022, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.

[30]  Yan Liang,et al.  Interactions between gut microbiota and Parkinson's disease: The role of microbiota-derived amino acid metabolism , 2022, Frontiers in Aging Neuroscience.

[31]  Y. Sung,et al.  HtrA2 regulates α-Synuclein-mediated mitochondrial reactive oxygen species production in the mitochondria of microglia. , 2022, Biochemical and biophysical research communications.

[32]  Chen Liang,et al.  Vagus Nerve and Underlying Impact on the Gut Microbiota-Brain Axis in Behavior and Neurodegenerative Diseases , 2022, Journal of inflammation research.

[33]  Farhan Mohammad,et al.  Gut microbiome and Parkinson's disease: Perspective on pathogenesis and treatment , 2022, Journal of advanced research.

[34]  W. Kim,et al.  LRRK2 and Lipid Pathways: Implications for Parkinson’s Disease , 2022, Biomolecules.

[35]  Z. Yue,et al.  Gut bacterial profiles in Parkinson's disease: A systematic review , 2022, CNS neuroscience & therapeutics.

[36]  Houeto Jean-Luc [Parkinson's disease]. , 2022, La Revue du praticien.

[37]  Scott D. Ryan,et al.  Nitrosative stress in Parkinson’s disease , 2022, npj Parkinson's Disease.

[38]  G. Logroscino,et al.  Descriptive Epidemiology of Neurodegenerative Diseases: What Are the Critical Questions? , 2022, Neuroepidemiology.

[39]  Xiaoying Gao,et al.  Mitochondrial Dysfunction in Parkinson’s Disease: From Mechanistic Insights to Therapy , 2022, Frontiers in Aging Neuroscience.

[40]  R. Krüger,et al.  Neurodegeneration and Neuroinflammation in Parkinson’s Disease: a Self-Sustained Loop , 2022, Current Neurology and Neuroscience Reports.

[41]  P. Verstreken,et al.  Parkinsonism mutations in DNAJC6 cause lipid defects and neurodegeneration that are rescued by Synj1 , 2022, bioRxiv.

[42]  U. Sengupta,et al.  Amyloid β, Tau, and α-Synuclein aggregates in the pathogenesis, prognosis, and therapeutics for neurodegenerative diseases , 2022, Progress in Neurobiology.

[43]  K. Del Tredici,et al.  Gastrointestinal involvement in Parkinson’s disease: pathophysiology, diagnosis, and management , 2022, NPJ Parkinson's disease.

[44]  M. Farrer,et al.  The Gut–Brain Axis and Its Relation to Parkinson’s Disease: A Review , 2022, Frontiers in Aging Neuroscience.

[45]  M. Sommerauer,et al.  Clinical and imaging evidence of brain-first and body-first Parkinson's disease , 2022, Neurobiology of Disease.

[46]  Chih-Chiang Chan,et al.  Mitochondrial Function and Parkinson’s Disease: From the Perspective of the Electron Transport Chain , 2021, Frontiers in Molecular Neuroscience.

[47]  J. Trojanowski,et al.  Alpha-synuclein from patient Lewy bodies exhibits distinct pathological activity that can be propagated in vitro , 2021, Acta neuropathologica communications.

[48]  Chun-Pai Yang,et al.  The Association of Olfactory Dysfunction With Depression, Cognition, and Disease Severity in Parkinson's Disease , 2021, Frontiers in Neurology.

[49]  K. Satoh,et al.  Tyrosine 136 phosphorylation of α-synuclein aggregates in the Lewy body dementia brain: involvement of serine 129 phosphorylation by casein kinase 2 , 2021, Acta Neuropathologica Communications.

[50]  S. Shukla,et al.  Non-motor symptoms in Parkinson's disease: Opening new avenues in treatment , 2021 .

[51]  M. Muqit,et al.  PTEN-induced kinase 1 (PINK1) and Parkin: Unlocking a mitochondrial quality control pathway linked to Parkinson's disease , 2021, Current Opinion in Neurobiology.

[52]  R. Rajasekaran,et al.  Alpha-Synuclein Aggregation in Parkinson's Disease , 2021, Frontiers in Medicine.

[53]  D. Choi,et al.  Targeting α‐synuclein aggregation and its role in mitochondrial dysfunction in Parkinson's disease , 2021, British journal of pharmacology.

[54]  M. Chartier-Harlin,et al.  Alpha-Synuclein and Lipids: The Elephant in the Room? , 2021, Cells.

[55]  R. Matthiesen,et al.  Glycation modulates glutamatergic signaling and exacerbates Parkinson’s disease-like phenotypes , 2021, npj Parkinson's Disease.

[56]  S. Pieraccini,et al.  α-Synuclein: An All-Inclusive Trip Around its Structure, Influencing Factors and Applied Techniques , 2021, Frontiers in Chemistry.

[57]  D. Aarsland,et al.  Parkinson disease-associated cognitive impairment , 2021, Nature Reviews Disease Primers.

[58]  Jacob O Day,et al.  The Genetics of Parkinson’s Disease and Implications for Clinical Practice , 2021, Genes.

[59]  H. Choi,et al.  Recent advances in the pathology of prodromal non-motor symptoms olfactory deficit and depression in Parkinson’s disease: clues to early diagnosis and effective treatment , 2021, Archives of Pharmacal Research.

[60]  K. Chaudhuri,et al.  Gastrointestinal dysfunction in Parkinson’s disease: molecular pathology and implications of gut microbiome, probiotics, and fecal microbiota transplantation , 2021, Journal of Neurology.

[61]  K. Bötzel,et al.  Pathophysiological Changes in the Enteric Nervous System of Rotenone-Exposed Mice as Early Radiological Markers for Parkinson's Disease , 2021, Frontiers in Neurology.

[62]  T. Dawson,et al.  The cell biology of Parkinson’s disease , 2021, The Journal of cell biology.

[63]  I. Charles,et al.  Meta-analysis of the Parkinson’s disease gut microbiome suggests alterations linked to intestinal inflammation , 2021, NPJ Parkinson's disease.

[64]  D. Brooks,et al.  Preserved noradrenergic function in Parkinson's disease patients with rest tremor , 2021, Neurobiology of Disease.

[65]  Safeera Khan,et al.  Spectrum of Non-Motor Symptoms in Parkinson's Disease , 2021, Cureus.

[66]  V. R. Muddapu,et al.  Influence of energy deficiency on the subcellular processes of Substantia Nigra Pars Compacta cell for understanding Parkinsonian neurodegeneration , 2021, Scientific Reports.

[67]  Dan Li,et al.  Hierarchical chemical determination of amyloid polymorphs in neurodegenerative disease , 2021, Nature Chemical Biology.

[68]  G. Miller,et al.  Restoration of Noradrenergic Function in Parkinson’s Disease Model Mice , 2021, ASN neuro.

[69]  B. Tang,et al.  Olfactory Dysfunction Predicts Disease Progression in Parkinson’s Disease: A Longitudinal Study , 2020, Frontiers in Neuroscience.

[70]  M. Kowalska,et al.  Oxidative stress factors in Parkinson’s disease , 2020, Neural regeneration research.

[71]  E. Khedr,et al.  Depression and anxiety among patients with Parkinson’s disease: frequency, risk factors, and impact on quality of life , 2020, The Egyptian Journal of Neurology, Psychiatry and Neurosurgery.

[72]  O. Rötzschke,et al.  New Insights into Immune-Mediated Mechanisms in Parkinson’s Disease , 2020, International journal of molecular sciences.

[73]  Fushun Wang,et al.  Molecular Mechanisms of Glutamate Toxicity in Parkinson’s Disease , 2020, Frontiers in Neuroscience.

[74]  M. Martínez-Vicente,et al.  The Emerging Role of the Lysosome in Parkinson’s Disease , 2020, Cells.

[75]  N. Maiti,et al.  Structure Specific Neuro-toxicity of α-Synuclein Oligomer , 2020, bioRxiv.

[76]  Orly Halperin,et al.  Overconfidence in visual perception in Parkinson’s disease , 2020, bioRxiv.

[77]  M. Tremblay,et al.  Glutamate-induced excitotoxicity in Parkinson's disease: The role of glial cells. , 2020, Journal of pharmacological sciences.

[78]  Kuo-Hsuan Chang,et al.  The Role of Oxidative Stress in Parkinson’s Disease , 2020, Antioxidants.

[79]  J. Jankovic,et al.  Parkinson’s disease: etiopathogenesis and treatment , 2020, Journal of Neurology, Neurosurgery, and Psychiatry.

[80]  P. Yu,et al.  Correction: S-Nitrosylation of G protein-coupled receptor kinase 6 and Casein kinase 2 alpha modulates their kinase activity toward alpha-synuclein phosphorylation in an animal model of Parkinson’s disease , 2020, PloS one.

[81]  Suneil K. Kalia,et al.  LRRK2 and α-Synuclein: Distinct or Synergistic Players in Parkinson’s Disease? , 2020, Frontiers in Neuroscience.

[82]  J. Jankovic,et al.  Parkinson disease and the immune system — associations, mechanisms and therapeutics , 2020, Nature Reviews Neurology.

[83]  P. De Deurwaerdère,et al.  The Noradrenergic System in Parkinson’s Disease , 2020, Frontiers in Pharmacology.

[84]  Sarika Singh Noradrenergic pathways of locus coeruleus in Parkinson’s and Alzheimer’s pathology , 2020, The International journal of neuroscience.

[85]  Suneil K. Kalia,et al.  Early-onset impairment of the ubiquitin-proteasome system in dopaminergic neurons caused by α-synuclein , 2020, Acta Neuropathologica Communications.

[86]  L. Hool,et al.  L-type Ca2+ channel–mediated Ca2+ influx adjusts neuronal mitochondrial function to physiological and pathophysiological conditions , 2020, Science Signaling.

[87]  P. Agarwal,et al.  Depression and Anxiety in Parkinson Disease. , 2020, Clinics in geriatric medicine.

[88]  P. Heckman,et al.  The contribution of Parkin, PINK1 and DJ‐1 genes to selective neuronal degeneration in Parkinson's disease , 2020, The European journal of neuroscience.

[89]  A. Singleton,et al.  Genetics of Parkinson's disease: An introspection of its journey towards precision medicine , 2020, Neurobiology of Disease.

[90]  Dan Li,et al.  Structural diversity of amyloid fibrils and advances in their structure determination. , 2020, Biochemistry.

[91]  P. McLean,et al.  Alpha-synuclein-induced mitochondrial dysfunction is mediated via a sirtuin 3-dependent pathway , 2020, Molecular Neurodegeneration.

[92]  A. Albanese,et al.  VPS35-Based Approach: A Potential Innovative Treatment in Parkinson's Disease , 2019, Front. Neurol..

[93]  Seong-Tshool Hong,et al.  Neuroprotective function of Omi to α-synuclein-induced neurotoxicity , 2019, Neurobiology of Disease.

[94]  R. Wade-Martins,et al.  Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease , 2019, Front. Mol. Neurosci..

[95]  Susan S. Taylor,et al.  The In Situ Structure of Parkinson’s Disease-Linked LRRK2 , 2019, Cell.

[96]  Deming Zhao,et al.  The Role of the Gut Microbiota in the Pathogenesis of Parkinson's Disease , 2019, Front. Neurol..

[97]  H. Berendse,et al.  Hyposmia as a marker of (non-)motor disease severity in Parkinson’s disease , 2019, Journal of Neural Transmission.

[98]  K. Yung,et al.  Roles of Glutamate Receptors in Parkinson’s Disease , 2019, International journal of molecular sciences.

[99]  S. Chandra,et al.  Role of the endolysosomal system in Parkinson’s disease , 2019, Journal of neurochemistry.

[100]  E. Sidransky,et al.  Glucocerebrosidase and its relevance to Parkinson disease , 2019, Molecular Neurodegeneration.

[101]  Nikhil Panicker,et al.  Transneuronal Propagation of Pathologic α-Synuclein from the Gut to the Brain Models Parkinson’s Disease , 2019, Neuron.

[102]  L. Bubacco,et al.  Impaired dopamine metabolism in Parkinson’s disease pathogenesis , 2019, Molecular Neurodegeneration.

[103]  S. Ho,et al.  The interplay of aging, genetics and environmental factors in the pathogenesis of Parkinson’s disease , 2019, Translational Neurodegeneration.

[104]  M. T. Pellecchia,et al.  Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study , 2019, The Lancet Neurology.

[105]  D. Fairlie,et al.  Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles , 2019, Molecular Neurodegeneration.

[106]  Michael D Healy,et al.  Towards a molecular understanding of endosomal trafficking by Retromer and Retriever , 2019, Traffic.

[107]  D. Eidelberg,et al.  Serotonergic pathology and Braak's staging hypothesis in Parkinson's disease , 2019, The Lancet Neurology.

[108]  Matthew J. Summers Ubiquitin Proteasome System - Current Insights into Mechanism Cellular Regulation and Disease , 2019 .

[109]  A. Xie,et al.  Prion-Like Mechanisms in Parkinson’s Disease , 2019, Front. Neurosci..

[110]  T. Graham,et al.  Mammalian retromer is an adaptable scaffold for cargo sorting from endosomes , 2019, bioRxiv.

[111]  J. Koistinaho,et al.  Dysfunction of Cellular Proteostasis in Parkinson’s Disease , 2019, Front. Neurosci..

[112]  V. Zinchenko,et al.  Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease , 2019, Journal of Bioenergetics and Biomembranes.

[113]  Jia-Da Li,et al.  The Roles of Post-translational Modifications on α-Synuclein in the Pathogenesis of Parkinson’s Diseases , 2019, Front. Neurosci..

[114]  W. Teo,et al.  Parkinson's Disease and the Environment , 2019, Front. Neurol..

[115]  Alexandra B. Nelson,et al.  Circuit Mechanisms of Parkinson’s Disease , 2019, Neuron.

[116]  Hui Zhang,et al.  LRRK2 and mitochondria: Recent advances and current views , 2019, Brain Research.

[117]  J. Greenland,et al.  Parkinson’s Disease: Pathogenesis and Clinical Aspects , 2018 .

[118]  L. Brodin,et al.  Retromer in Synaptic Function and Pathology , 2018, Front. Synaptic Neurosci..

[119]  H. Ni,et al.  The Role of LRRK2 in Neurodegeneration of Parkinson Disease , 2018, Current neuropharmacology.

[120]  J. Błaszczyk The Emerging Role of Energy Metabolism and Neuroprotective Strategies in Parkinson's Disease , 2018, Front. Aging Neurosci..

[121]  H. Düssmann,et al.  ER stress signaling has an activating transcription factor 6α (ATF6)-dependent “off-switch” , 2018, The Journal of Biological Chemistry.

[122]  Wei He,et al.  Tau Pathology in Parkinson's Disease , 2018, Front. Neurol..

[123]  M. Tansey,et al.  α-Synuclein and Noradrenergic Modulation of Immune Cells in Parkinson’s Disease Pathogenesis , 2018, Front. Neurosci..

[124]  E. Mariman,et al.  Differential protein expression of hippocampal cells associated with heavy metals (Pb, As, and MeHg) neurotoxicity: Deepening into the molecular mechanism of neurodegenerative diseases. , 2018, Journal of proteomics.

[125]  R. Teasdale,et al.  Structure of the membrane-assembled retromer coat determined by cryo-electron tomography , 2018, Nature.

[126]  M. Rao,et al.  Enteric nervous system manifestations of neurodegenerative disease , 2018, Brain Research.

[127]  H. Mortiboys,et al.  Mitochondrial abnormalities in Parkinson's disease and Alzheimer's disease: can mitochondria be targeted therapeutically? , 2018, Biochemical Society transactions.

[128]  Hossein Sanjari Moghaddam,et al.  Cerebrospinal Fluid C-Reactive Protein in Parkinson’s Disease: Associations with Motor and Non-motor Symptoms , 2018, NeuroMolecular Medicine.

[129]  D. Krainc,et al.  Molecular mechanisms of α-synuclein and GBA1 in Parkinson’s disease , 2018, Cell and Tissue Research.

[130]  C. Duyckaerts,et al.  Is Lewy pathology in the human nervous system chiefly an indicator of neuronal protection or of toxicity? , 2018, Cell and Tissue Research.

[131]  Joseph R. Patterson,et al.  Induction of alpha-synuclein pathology in the enteric nervous system of the rat and non-human primate results in gastrointestinal dysmotility and transient CNS pathology , 2018, Neurobiology of Disease.

[132]  R. Moratalla,et al.  Cholesterol and multilamellar bodies: Lysosomal dysfunction in GBA-Parkinson disease , 2018, Autophagy.

[133]  K. Jellinger,et al.  Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease? , 2018, BMC Medicine.

[134]  T. Südhof,et al.  Cell Biology and Pathophysiology of α-Synuclein. , 2018, Cold Spring Harbor perspectives in medicine.

[135]  Romain F. Laine,et al.  C-terminal calcium binding of α-synuclein modulates synaptic vesicle interaction , 2018, Nature Communications.

[136]  M. Sakharkar,et al.  Naringenin Decreases α-Synuclein Expression and Neuroinflammation in MPTP-Induced Parkinson’s Disease Model in Mice , 2018, Neurotoxicity Research.

[137]  Shi-feng Chu,et al.  RTP801 is a critical factor in the neurodegeneration process of A53T α‐synuclein in a mouse model of Parkinson's disease under chronic restraint stress , 2018, British journal of pharmacology.

[138]  D. Standaert,et al.  Peripheral monocyte entry is required for alpha-Synuclein induced inflammation and Neurodegeneration in a model of Parkinson disease , 2018, Experimental Neurology.

[139]  M. Mattson,et al.  Intercellular transfer of pathogenic α-synuclein by extracellular vesicles is induced by the lipid peroxidation product 4-hydroxynonenal , 2018, Neurobiology of Aging.

[140]  L. Sanders,et al.  Alpha-synuclein: Pathology, mitochondrial dysfunction and neuroinflammation in Parkinson’s disease , 2018, Neurobiology of Disease.

[141]  A. Pandey,et al.  GBA1 deficiency negatively affects physiological α-synuclein tetramers and related multimers , 2018, Proceedings of the National Academy of Sciences.

[142]  G. Novelli,et al.  Genetics and Treatment Response in Parkinson’s Disease: An Update on Pharmacogenetic Studies , 2018, NeuroMolecular Medicine.

[143]  David S. Park,et al.  Guidelines on experimental methods to assess mitochondrial dysfunction in cellular models of neurodegenerative diseases , 2017, Cell Death & Differentiation.

[144]  T. Amstislavskaya,et al.  Suppression of autophagy in the brain of transgenic mice with overexpression of А53Т-mutant α-synuclein as an early event at synucleinopathy progression , 2017, Neuroscience Letters.

[145]  L. Bubacco,et al.  Recent findings on the physiological function of DJ-1: Beyond Parkinson's disease , 2017, Neurobiology of Disease.

[146]  T. Gasser,et al.  LRRK2 functions as a scaffolding kinase of ASK1-mediated neuronal cell death. , 2017, Biochimica et biophysica acta. Molecular cell research.

[147]  O. El‐Agnaf,et al.  Phosphorylated exogenous alpha-synuclein fibrils exacerbate pathology and induce neuronal dysfunction in mice , 2017, Scientific Reports.

[148]  J. V. Van Raamsdonk,et al.  Activation of the mitochondrial unfolded protein response promotes longevity and dopamine neuron survival in Parkinson’s disease models , 2017, Scientific Reports.

[149]  P. Hof,et al.  Parkinson's Disease-Associated LRRK2 Hyperactive Kinase Mutant Disrupts Synaptic Vesicle Trafficking in Ventral Midbrain Neurons , 2017, The Journal of Neuroscience.

[150]  Alex R. Wade,et al.  Abnormal visual gain control and excitotoxicity in early-onset Parkinson’s disease Drosophila models , 2017, Journal of neurophysiology.

[151]  K. Caldwell,et al.  Dysregulation of the Mitochondrial Unfolded Protein Response Induces Non-Apoptotic Dopaminergic Neurodegeneration in C. elegans Models of Parkinson's Disease , 2017, The Journal of Neuroscience.

[152]  E. H. Howlett,et al.  LRRK2 G2019S-induced mitochondrial DNA damage is LRRK2 kinase dependent and inhibition restores mtDNA integrity in Parkinson’s disease , 2017, Human molecular genetics.

[153]  Andrew R. Bassett,et al.  Alpha-synuclein induces the unfolded protein response in Parkinson’s disease SNCA triplication iPSC-derived neurons , 2017, Human molecular genetics.

[154]  Matthias Mann,et al.  Systematic proteomic analysis of LRRK2-mediated Rab GTPase phosphorylation establishes a connection to ciliogenesis , 2017, eLife.

[155]  David S. Park,et al.  PINK1-mediated phosphorylation of LETM1 regulates mitochondrial calcium transport and protects neurons against mitochondrial stress , 2017, Nature Communications.

[156]  S. Signorelli,et al.  Metals and neurodegenerative diseases. A systematic review , 2017, Environmental research.

[157]  S. Schneider,et al.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature , 2017, Movement disorders : official journal of the Movement Disorder Society.

[158]  Ori J. Lieberman,et al.  α-Synuclein-Dependent Calcium Entry Underlies Differential Sensitivity of Cultured SN and VTA Dopaminergic Neurons to a Parkinsonian Neurotoxin , 2017, eNeuro.

[159]  Wenzhang Wang,et al.  Parkinson's disease-associated pathogenic VPS35 mutation causes complex I deficits. , 2017, Biochimica et biophysica acta. Molecular basis of disease.

[160]  Songhee Jeon,et al.  MPTP-induced vulnerability of dopamine neurons in A53T α-synuclein overexpressed mice with the potential involvement of DJ-1 downregulation , 2017, The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology.

[161]  D. Murry,et al.  Inactivation of glyceraldehyde-3-phosphate dehydrogenase by the dopamine metabolite, 3,4-dihydroxyphenylacetaldehyde. , 2017, Biochemical and biophysical research communications.

[162]  P. Brundin,et al.  Prying into the Prion Hypothesis for Parkinson's Disease , 2017, The Journal of Neuroscience.

[163]  Yung-Yee Chang,et al.  Identification of VPS35 p.D620N mutation-related Parkinson’s disease in a Taiwanese family with successful bilateral subthalamic nucleus deep brain stimulation: a case report and literature review , 2017, BMC Neurology.

[164]  S. Chandra,et al.  Glucosylsphingosine Promotes α-Synuclein Pathology in Mutant GBA-Associated Parkinson's Disease , 2017, The Journal of Neuroscience.

[165]  M. Romero-Ramos,et al.  Allelic difference in Mhc2ta confers altered microglial activation and susceptibility to α-synuclein-induced dopaminergic neurodegeneration , 2017, Neurobiology of Disease.

[166]  H. Broxmeyer,et al.  Parkinson disease–associated LRRK2 G2019S transgene disrupts marrow myelopoiesis and peripheral Th17 response , 2017, Journal of leukocyte biology.

[167]  S. Zanata,et al.  ER Stress Induced by Tunicamycin Triggers α-Synuclein Oligomerization, Dopaminergic Neurons Death and Locomotor Impairment: a New Model of Parkinson’s Disease , 2017, Molecular Neurobiology.

[168]  Jun Liu,et al.  DJ-1 Inhibits α-Synuclein Aggregation by Regulating Chaperone-Mediated Autophagy , 2017, Front. Aging Neurosci..

[169]  Jochen H Weishaupt,et al.  Proteasome impairment by α-synuclein , 2017, PloS one.

[170]  Sohee Jeon,et al.  Dopamine oxidation mediates mitochondrial and lysosomal dysfunction in Parkinson’s disease , 2017, Science.

[171]  D. V. van Aalten,et al.  Structure of PINK1 and mechanisms of Parkinson's disease-associated mutations , 2017, eLife.

[172]  K. Ye,et al.  TrkB neurotrophic activities are blocked by α-synuclein, triggering dopaminergic cell death in Parkinson’s disease , 2017, Proceedings of the National Academy of Sciences.

[173]  R. Kalb,et al.  Dopamine induces soluble α-synuclein oligomers and nigrostriatal degeneration , 2017, Nature Neuroscience.

[174]  W. Banks,et al.  Transmission of α-synuclein-containing erythrocyte-derived extracellular vesicles across the blood-brain barrier via adsorptive mediated transcytosis: another mechanism for initiation and progression of Parkinson’s disease? , 2017, Acta Neuropathologica Communications.

[175]  A. Schapira,et al.  The L444P Gba1 mutation enhances alpha-synuclein induced loss of nigral dopaminergic neurons in mice , 2017, Brain : a journal of neurology.

[176]  M. Cookson,et al.  Alpha‐synuclein triggers T‐cell response. Is Parkinson's disease an autoimmune disorder? , 2017, Movement disorders : official journal of the Movement Disorder Society.

[177]  P. Su,et al.  A peptide disrupting the D2R-DAT interaction protects against dopamine neurotoxicity , 2017, Experimental Neurology.

[178]  K. Lim,et al.  Reactive oxygen species trigger Parkin/PINK1 pathway–dependent mitophagy by inducing mitochondrial recruitment of Parkin , 2017, The Journal of Biological Chemistry.

[179]  P. Calabresi,et al.  Cerebrospinal fluid β‐glucocerebrosidase activity is reduced in parkinson's disease patients , 2017, Movement disorders : official journal of the Movement Disorder Society.

[180]  J. Kulisevsky,et al.  N370S‐GBA1 mutation causes lysosomal cholesterol accumulation in Parkinson's disease , 2017, Movement disorders : official journal of the Movement Disorder Society.

[181]  D. Meierhofer,et al.  Progression of pathology in PINK1-deficient mouse brain from splicing via ubiquitination, ER stress, and mitophagy changes to neuroinflammation , 2017, Journal of Neuroinflammation.

[182]  H. Erdjument-Bromage,et al.  The Ubiquitination of PINK1 Is Restricted to Its Mature 52-kDa Form , 2017, Cell reports.

[183]  R. Martino,et al.  Onset and progression factors in Parkinson's disease: A systematic review , 2017, Neurotoxicology.

[184]  Thomas Theelen,et al.  Ocular and visual disorders in Parkinson's disease: Common but frequently overlooked. , 2017, Parkinsonism & related disorders.

[185]  Min Zhu,et al.  DJ-1, a Parkinson's disease related protein, aggregates under denaturing conditions and co-aggregates with α-synuclein through hydrophobic interaction. , 2017, Biochimica et biophysica acta. General subjects.

[186]  E. Masliah,et al.  Synuclein impairs trafficking and signaling of BDNF in a mouse model of Parkinson’s disease , 2017, Scientific Reports.

[187]  S. Koyama,et al.  Mechanisms underlying extensive Ser129-phosphorylation in α-synuclein aggregates , 2017, Acta neuropathologica communications.

[188]  K. Chaudhuri,et al.  Non-motor features of Parkinson disease , 2017, Nature Reviews Neuroscience.

[189]  C. Crosio,et al.  Role of LRRK2 in the regulation of dopamine receptor trafficking , 2017, PloS one.

[190]  T. Asil,et al.  Motor and Non-Motor Symptoms in Parkinson's Disease: Effects on Quality of Life. , 2017, Noro psikiyatri arsivi.

[191]  S. Zaichick,et al.  The role of Ca2+ signaling in Parkinson's disease , 2017, Disease Models & Mechanisms.

[192]  Z. Wszolek,et al.  The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity , 2017, Molecular Neurodegeneration.

[193]  M. Muqit,et al.  PINK1 and Parkin: emerging themes in mitochondrial homeostasis. , 2017, Current opinion in cell biology.

[194]  N. Bouslam,et al.  LRRK2 G2019S Mutation: Prevalence and Clinical Features in Moroccans with Parkinson's Disease , 2017, Parkinson's disease.

[195]  J. Segura-Aguilar,et al.  Are Dopamine Oxidation Metabolites Involved in the Loss of Dopaminergic Neurons in the Nigrostriatal System in Parkinson's Disease? , 2017, ACS chemical neuroscience.

[196]  W. Meissner,et al.  Epidemiology, environmental risk factors and genetics of Parkinson's disease. , 2017, Presse medicale.

[197]  J. Massano,et al.  An updated review of Parkinson's disease genetics and clinicopathological correlations , 2017, Acta neurologica Scandinavica.

[198]  I. Toni,et al.  Dopamine controls Parkinson’s tremor by inhibiting the cerebellar thalamus , 2017, Brain : a journal of neurology.

[199]  Matthieu Drouyer,et al.  LRRK2 detection in human biofluids: potential use as a Parkinson's disease biomarker? , 2017, Biochemical Society transactions.

[200]  T. Dawson,et al.  PINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival. , 2017, Cell reports.

[201]  She Chen,et al.  PINK1-dependent phosphorylation of PINK1 and Parkin is essential for mitochondrial quality control , 2016, Cell Death & Disease.

[202]  J. Bonifacino,et al.  Structural Mechanism for Cargo Recognition by the Retromer Complex , 2016, Cell.

[203]  P. Wang,et al.  Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity , 2016, Parkinson's disease.

[204]  M. Farrer,et al.  Heterozygous PINK1 p.G411S increases risk of Parkinson’s disease via a dominant-negative mechanism , 2016, Brain : a journal of neurology.

[205]  K. Chung,et al.  Leucine-rich repeat kinase 2 exacerbates neuronal cytotoxicity through phosphorylation of histone deacetylase 3 and histone deacetylation , 2016, Human molecular genetics.

[206]  T. Monks,et al.  From the Cover: Arsenic Induces Accumulation of α-Synuclein: Implications for Synucleinopathies and Neurodegeneration. , 2016, Toxicological sciences : an official journal of the Society of Toxicology.

[207]  Kwang-Soo Kim,et al.  LRRK2 interferes with aggresome formation for autophagic clearance , 2016, Molecular and Cellular Neuroscience.

[208]  J. Troncoso,et al.  Activation of tyrosine kinase c-Abl contributes to α-synuclein-induced neurodegeneration. , 2016, The Journal of clinical investigation.

[209]  D. Krainc,et al.  Activation of β-Glucocerebrosidase Reduces Pathological α-Synuclein and Restores Lysosomal Function in Parkinson's Patient Midbrain Neurons , 2016, The Journal of Neuroscience.

[210]  H. McBride,et al.  Parkinson’s Disease-Related Proteins PINK1 and Parkin Repress Mitochondrial Antigen Presentation , 2016, Cell.

[211]  Andrew B West,et al.  G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons , 2016, The Journal of Neuroscience.

[212]  R. Teasdale,et al.  Parkinson Disease-linked Vps35 R524W Mutation Impairs the Endosomal Association of Retromer and Induces α-Synuclein Aggregation* , 2016, The Journal of Biological Chemistry.

[213]  N. Wood,et al.  Mitofusin-mediated ER stress triggers neurodegeneration in pink1/parkin models of Parkinson's disease , 2016, Cell Death and Disease.

[214]  I. Alonso,et al.  DJ-1 linked parkinsonism (PARK7) is associated with Lewy body pathology. , 2016, Brain : a journal of neurology.

[215]  Mandar S Jog,et al.  An update on the diagnosis and treatment of Parkinson disease , 2016, Canadian Medical Association Journal.

[216]  N. Quan,et al.  Neuroinflammation: the devil is in the details , 2016, Journal of neurochemistry.

[217]  Yuanjun Guo,et al.  Long Non-coding RNA HOTAIR Promotes Parkinson's Disease Induced by MPTP Through up-regulating the Expression of LRRK2. , 2016, Current neurovascular research.

[218]  Charles D. Schwieters,et al.  Solid-State NMR Structure of a Pathogenic Fibril of Full-Length Human α-Synuclein , 2016, Nature Structural &Molecular Biology.

[219]  E. Balafas,et al.  GABA transmission via ATP-dependent K+ channels regulates α-synuclein secretion in mouse striatum. , 2016, Brain : a journal of neurology.

[220]  C. Ross,et al.  Synphilin-1 attenuates mutant LRRK2-induced neurodegeneration in Parkinson's disease models. , 2016, Human molecular genetics.

[221]  J. Winkler,et al.  Severely impaired hippocampal neurogenesis associates with an early serotonergic deficit in a BAC α-synuclein transgenic rat model of Parkinson's disease , 2016, Neurobiology of Disease.

[222]  D. Turnbull,et al.  Mitochondrial DNA Depletion in Respiratory Chain–Deficient Parkinson Disease Neurons , 2016, Annals of neurology.

[223]  A. Schapira,et al.  Endoplasmic reticulum and lysosomal Ca2+ stores are remodelled in GBA1-linked Parkinson disease patient fibroblasts , 2016, Cell calcium.

[224]  M. Murray,et al.  Transmission of Soluble and Insoluble &agr;-Synuclein to Mice , 2015, Journal of neuropathology and experimental neurology.

[225]  D. Hausenloy,et al.  Parkinson's disease proteins: Novel mitochondrial targets for cardioprotection , 2015, Pharmacology & therapeutics.

[226]  P. Chinnery,et al.  Mitochondrial dysfunction in aging: Much progress but many unresolved questions , 2015, Biochimica et biophysica acta.

[227]  G. Kim,et al.  The Role of Oxidative Stress in Neurodegenerative Diseases , 2015, Experimental neurobiology.

[228]  B. Pakkenberg,et al.  Lack of Neuronal IFN-β-IFNAR Causes Lewy Body- and Parkinson’s Disease-like Dementia , 2015, Cell.

[229]  Wenzhang Wang,et al.  Parkinson’s disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes , 2015, Nature Medicine.

[230]  P. Mastroberardino,et al.  Metals and neurodegeneration , 2015, Neurobiology of Disease.

[231]  Nicholas K. Sauter,et al.  Structure of the toxic core of α-synuclein from invisible crystals , 2015, Nature.

[232]  L. Mei,et al.  VPS35 Deficiency or Mutation Causes Dopaminergic Neuronal Loss by Impairing Mitochondrial Fusion and Function. , 2015, Cell reports.

[233]  S. Weber,et al.  Exogenous α-synuclein induces toll-like receptor 4 dependent inflammatory responses in astrocytes , 2015, BMC Neuroscience.

[234]  J. Burman,et al.  The ubiquitin kinase PINK1 recruits autophagy receptors to induce mitophagy , 2015, Nature.

[235]  W. Scheper,et al.  The unfolded protein response in neurodegenerative diseases: a neuropathological perspective , 2015, Acta Neuropathologica.

[236]  Victor Tapias,et al.  shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model. , 2015, The Journal of clinical investigation.

[237]  S. Paek,et al.  Mitochondrial Dysfunction in Parkinson's Disease , 2015, Experimental neurobiology.

[238]  V. Rao,et al.  Evaluation of PARKIN gene variants in West Bengal Parkinson’s disease patients , 2015, Journal of Human Genetics.

[239]  A. Schapira Glucocerebrosidase and Parkinson disease: Recent advances , 2015, Molecular and Cellular Neuroscience.

[240]  C. Gerloff,et al.  Visual Attention and Saccadic Oculomotor Control in Parkinson's Disease , 2015, European Neurology.

[241]  B. Pająk,et al.  Calcium Homeostasis and ER Stress in Control of Autophagy in Cancer Cells , 2015, BioMed research international.

[242]  L. Aguayo,et al.  Extracellular α‐synuclein alters synaptic transmission in brain neurons by perforating the neuronal plasma membrane , 2015, Journal of neurochemistry.

[243]  Seokjoong Kim,et al.  Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation , 2015, Experimental & Molecular Medicine.

[244]  Laura M. Vecchio,et al.  Increased expression of the dopamine transporter leads to loss of dopamine neurons, oxidative stress and l-DOPA reversible motor deficits , 2015, Neurobiology of Disease.

[245]  O. Isacson,et al.  Progressive decline of glucocerebrosidase in aging and Parkinson's disease , 2015, Annals of Clinical and Translational Neurology.

[246]  R. Youle,et al.  The Roles of PINK1, Parkin, and Mitochondrial Fidelity in Parkinson’s Disease , 2015, Neuron.

[247]  N. Alenina,et al.  The role of serotonin in adult hippocampal neurogenesis , 2015, Behavioural Brain Research.

[248]  A. Jeans,et al.  Is Parkinson's Disease Truly a Prion-Like Disorder? An Appraisal of Current Evidence , 2015, Neurology research international.

[249]  A. Wen,et al.  Protective Effects of Lycium barbarum Polysaccharide on 6-OHDA-Induced Apoptosis in PC12 Cells through the ROS-NO Pathway , 2014, Molecules.

[250]  G. Forloni,et al.  The Parkinson's Disease-Related Protein DJ-1 Protects Dopaminergic Neurons in vivo and Cultured Cells from Alpha-Synuclein and 6-Hydroxydopamine Toxicity , 2014, Neurodegenerative Diseases.

[251]  N. Jetté,et al.  The prevalence of Parkinson's disease: A systematic review and meta‐analysis , 2014, Movement disorders : official journal of the Movement Disorder Society.

[252]  S. Frautschy,et al.  Molecular Chaperone Dysfunction in Neurodegenerative Diseases and Effects of Curcumin , 2014, BioMed research international.

[253]  Yi Zhao,et al.  In vivo evidence of pathogenicity of VPS35 mutations in the Drosophila , 2014, Molecular Brain.

[254]  G. Halliday,et al.  Alpha-synuclein biology in Lewy body diseases , 2014, Alzheimer's Research & Therapy.

[255]  J. Goodwin,et al.  Interactions between Calcium and Alpha-Synuclein in Neurodegeneration , 2014, Biomolecules.

[256]  E. Bézard,et al.  Lysosomes and α-synuclein form a dangerous duet leading to neuronal cell death , 2014, Front. Neuroanat..

[257]  S. Lindquist,et al.  Calcineurin determines toxic versus beneficial responses to α-synuclein , 2014, Proceedings of the National Academy of Sciences.

[258]  Chuong B. Do,et al.  Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson’s disease , 2014, Nature Genetics.

[259]  M. Repici,et al.  DJ-1 interactions with α-synuclein attenuate aggregation and cellular toxicity in models of Parkinson's disease , 2014, Cell Death and Disease.

[260]  D. Selkoe,et al.  Soluble, Prefibrillar α-Synuclein Oligomers Promote Complex I-dependent, Ca2+-induced Mitochondrial Dysfunction* , 2014, The Journal of Biological Chemistry.

[261]  Bidisha Roy,et al.  Interactions between Tau and α-synuclein augment neurotoxicity in a Drosophila model of Parkinson's disease. , 2014, Human molecular genetics.

[262]  Soojay Banerjee,et al.  PINK1 phosphorylates ubiquitin to activate Parkin E3 ubiquitin ligase activity , 2014, The Journal of cell biology.

[263]  C. Hetz,et al.  Control of dopaminergic neuron survival by the unfolded protein response transcription factor XBP1 , 2014, Proceedings of the National Academy of Sciences.

[264]  D. Sulzer,et al.  MHC-I expression renders catecholaminergic neurons susceptible to T-cell-mediated degeneration , 2014, Nature Communications.

[265]  Heung-Chin Cheng,et al.  Prediction of the Repeat Domain Structures and Impact of Parkinsonism‐Associated Variations on Structure and Function of all Functional Domains of Leucine‐Rich Repeat Kinase 2 (LRRK2) , 2014, Human mutation.

[266]  S. Tenreiro,et al.  Protein phosphorylation in neurodegeneration: friend or foe? , 2014, Front. Mol. Neurosci..

[267]  A. Velázquez‐Campoy,et al.  Structural and Functional Analysis of Novel Human Cytochrome c Targets in Apoptosis* , 2014, Molecular & Cellular Proteomics.

[268]  G. Halliday,et al.  Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease. , 2014, Brain : a journal of neurology.

[269]  D. Turnbull,et al.  Ageing and Parkinson's disease: Why is advancing age the biggest risk factor?☆ , 2014, Ageing Research Reviews.

[270]  A. Destée,et al.  Involvement of the immune system, endocytosis and EIF2 signaling in both genetically determined and sporadic forms of Parkinson's disease , 2014, Neurobiology of Disease.

[271]  C. Burd,et al.  Retromer: a master conductor of endosome sorting. , 2014, Cold Spring Harbor perspectives in biology.

[272]  S. Goldman Environmental toxins and Parkinson's disease. , 2014, Annual review of pharmacology and toxicology.

[273]  R. Motter,et al.  In vivo modulation of polo-like kinases supports a key role for PLK2 in Ser129 α-synuclein phosphorylation in mouse brain , 2014, Neuroscience.

[274]  H. Mortiboys,et al.  Ursocholanic acid rescues mitochondrial function in common forms of familial Parkinson's disease. , 2013, Brain : a journal of neurology.

[275]  Xinglong Wang,et al.  Mitochondrial defects and oxidative stress in Alzheimer disease and Parkinson disease. , 2013, Free radical biology & medicine.

[276]  S. Fox Non-dopaminergic Treatments for Motor Control in Parkinson’s Disease , 2013, Drugs.

[277]  M. Chesselet,et al.  Mitochondrial dysfunction and oxidative stress in Parkinson's disease , 2013, Progress in Neurobiology.

[278]  D. Dexter,et al.  Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins. , 2013, Brain : a journal of neurology.

[279]  D. Standaert,et al.  MHCII Is Required for α-Synuclein-Induced Activation of Microglia, CD4 T Cell Proliferation, and Dopaminergic Neurodegeneration , 2013, The Journal of Neuroscience.

[280]  C. Klein,et al.  The many faces of alpha‐synuclein mutations , 2013, Movement disorders : official journal of the Movement Disorder Society.

[281]  Gunnar Brunborg,et al.  Metal Dyshomeostasis and Inflammation in Alzheimer's and Parkinson's Diseases: Possible Impact of Environmental Exposures , 2013, Oxidative medicine and cellular longevity.

[282]  E. Masliah,et al.  Neuron-released oligomeric α-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia , 2013, Nature Communications.

[283]  M. Duchen,et al.  Glucocerebrosidase inhibition causes mitochondrial dysfunction and free radical damage , 2013, Neurochemistry International.

[284]  Heung-Chin Cheng,et al.  Analysis of LRRK2 accessory repeat domains: prediction of repeat length, number and sites of Parkinson's disease mutations. , 2012, Biochemical Society transactions.

[285]  J. Hardy,et al.  Glucocerebrosidase Deficiency in Substantia Nigra of Parkinson Disease Brains , 2012, Annals of neurology.

[286]  M. Cookson Parkinsonism due to mutations in PINK1, parkin, and DJ-1 and oxidative stress and mitochondrial pathways. , 2012, Cold Spring Harbor perspectives in medicine.

[287]  A. Winslow,et al.  Exosomal cell-to-cell transmission of alpha synuclein oligomers , 2012, Molecular Neurodegeneration.

[288]  Xiaoguang Luo,et al.  Association of Parkinson’s disease with six single nucleotide polymorphisms located in four PARK genes in the northern Han Chinese population , 2012, Journal of Clinical Neuroscience.

[289]  T. Outeiro,et al.  Alpha-synuclein: from secretion to dysfunction and death , 2012, Cell Death and Disease.

[290]  N. Muzyczka,et al.  Glucose regulated protein 78 diminishes α-synuclein neurotoxicity in a rat model of Parkinson disease. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.

[291]  J. Im,et al.  DJ-1 induces thioredoxin 1 expression through the Nrf2 pathway. , 2012, Human molecular genetics.

[292]  S. Nataf,et al.  ER stress inhibits neuronal death by promoting autophagy , 2012, Autophagy.

[293]  M. Duchen,et al.  Dopamine Induced Neurodegeneration in a PINK1 Model of Parkinson's Disease , 2012, PloS one.

[294]  A. Schapira,et al.  A clinical and family history study of Parkinson's disease in heterozygous glucocerebrosidase mutation carriers , 2012, Journal of Neurology, Neurosurgery & Psychiatry.

[295]  L. Birnbaumer,et al.  Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. , 2012, The Journal of clinical investigation.

[296]  J. Troncoso,et al.  Endoplasmic Reticulum Stress Is Important for the Manifestations of α-Synucleinopathy In Vivo , 2012, The Journal of Neuroscience.

[297]  M. Rohde,et al.  Throughput optimized a-Si/μc-Si tandem solar cells on sputter-etched ZnO substrates , 2012 .

[298]  F. Sterky,et al.  Altered dopamine metabolism and increased vulnerability to MPTP in mice with partial deficiency of mitochondrial complex I in dopamine neurons. , 2012, Human molecular genetics.

[299]  Xiongwei Zhu,et al.  LRRK2 regulates mitochondrial dynamics and function through direct interaction with DLP1. , 2012, Human molecular genetics.

[300]  J. Cannon,et al.  The role of environmental exposures in neurodegeneration and neurodegenerative diseases. , 2011, Toxicological sciences : an official journal of the Society of Toxicology.

[301]  P. Walter,et al.  The Unfolded Protein Response: From Stress Pathway to Homeostatic Regulation , 2011, Science.

[302]  J. Sanders,et al.  Leucine-Rich Repeat Kinase 2 (LRRK2) Cellular Biology: A Review of Recent Advances in Identifying Physiological Substrates and Cellular Functions , 2011, Journal of neurogenetics.

[303]  S. Koyama,et al.  Authentically Phosphorylated α-Synuclein at Ser129 Accelerates Neurodegeneration in a Rat Model of Familial Parkinson's Disease , 2011, The Journal of Neuroscience.

[304]  U. Mosimann,et al.  Visual symptoms in Parkinson's disease and Parkinson's disease dementia , 2011, Movement disorders : official journal of the Movement Disorder Society.

[305]  I. Martin,et al.  Recent advances in the genetics of Parkinson's disease. , 2011, Annual review of genomics and human genetics.

[306]  F. Wang,et al.  GDNF-pretreatment enhances the survival of neural stem cells following transplantation in a rat model of Parkinson's disease , 2011, Neuroscience Research.

[307]  D. Rubinsztein,et al.  The Parkinson's disease protein LRRK2 impairs proteasome substrate clearance without affecting proteasome catalytic activity , 2011, Cell Death and Disease.

[308]  H. Adami,et al.  Epidemiology and etiology of Parkinson’s disease: a review of the evidence , 2011, European Journal of Epidemiology.

[309]  E. Masliah,et al.  Hyperphosphorylated Tau in an α‐synuclein‐overexpressing transgenic model of Parkinson’s disease , 2011, The European journal of neuroscience.

[310]  J. Zeng,et al.  LRRK2 R1398H polymorphism is associated with decreased risk of Parkinson's disease in a Han Chinese population. , 2011, Parkinsonism & related disorders.

[311]  D. Howells,et al.  Changes in the solubility and phosphorylation of α-synuclein over the course of Parkinson’s disease , 2011, Acta Neuropathologica.

[312]  H. Zhou,et al.  Confirmation of LRRK2 S1647T variant as a risk factor for Parkinson’s disease in Southern China , 2011, European journal of neurology.

[313]  B. Meier,et al.  Motor sequence learning performance in Parkinson’s disease patients depends on the stage of disease , 2011, Brain and Cognition.

[314]  Miguel Ángel Martínez,et al.  Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies , 2011, The Lancet.

[315]  Fred H. Gage,et al.  In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.

[316]  J. Pu,et al.  A study of six point mutation analysis of LRRK2 gene in Chinese mainland patients with Parkinson’s disease , 2011, Neurological Sciences.

[317]  W. Burke,et al.  The Neurotoxicity of DOPAL: Behavioral and Stereological Evidence for Its Role in Parkinson Disease Pathogenesis , 2010, PloS one.

[318]  Mark R. Cookson,et al.  The role of leucine-rich repeat kinase 2 (LRRK2) in Parkinson's disease , 2010, Nature Reviews Neuroscience.

[319]  C. Tanner,et al.  Familial aggregation of Parkinson's disease in a multiethnic community‐based case‐control study , 2010, Movement disorders : official journal of the Movement Disorder Society.

[320]  B. Giasson,et al.  L10p and P158DEL DJ‐1 mutations cause protein instability, aggregation, and dimerization impairments , 2010, Journal of neuroscience research.

[321]  I. Mata,et al.  The Genetics of Parkinson Disease , 2010, Journal of geriatric psychiatry and neurology.

[322]  B. Zhivotovsky,et al.  Mitochondrial regulation of cell death: processing of apoptosis-inducing factor (AIF). , 2010, Biochemical and biophysical research communications.

[323]  C. Sampaio,et al.  Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review. , 2010, Parkinsonism & related disorders.

[324]  R. de Silva,et al.  LRRK2 G2019S in the North African Population: A Review , 2010, European Neurology.

[325]  Hee-Jin Kim,et al.  The LRRK2 G2385R variant is a risk factor for sporadic Parkinson's disease in the Korean population. , 2010, Parkinsonism & related disorders.

[326]  R. Raghubir,et al.  Endoplasmic Reticulum Stress Plays Critical Role in Brain Damage After Cerebral Ischemia/Reperfusion in Rats , 2010, Neurotoxicity Research.

[327]  Bradley A. Evanoff,et al.  Geographic and Ethnic Variation in Parkinson Disease: A Population-Based Study of US Medicare Beneficiaries , 2010, Neuroepidemiology.

[328]  Atsushi Tanaka,et al.  PINK1 Is Selectively Stabilized on Impaired Mitochondria to Activate Parkin , 2010, PLoS biology.

[329]  M. Nalls,et al.  Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. , 2009, The New England journal of medicine.

[330]  Nir Giladi,et al.  The LRRK2 G2019S mutation as the cause of Parkinson’s disease in Ashkenazi Jews , 2009, Journal of Neural Transmission.

[331]  T. Niki,et al.  Oxidative Status of DJ-1-dependent Activation of Dopamine Synthesis through Interaction of Tyrosine Hydroxylase and 4-Dihydroxy-l-phenylalanine (l-DOPA) Decarboxylase with DJ-1* , 2009, The Journal of Biological Chemistry.

[332]  R. Youle,et al.  Parkin-induced mitophagy in the pathogenesis of Parkinson disease , 2009, Autophagy.

[333]  A. H. Tsang,et al.  Oxidative and nitrosative stress in Parkinson's disease. , 2009, Biochimica et biophysica acta.

[334]  Wolfgang Wurst,et al.  Loss of Parkin or PINK1 Function Increases Drp1-dependent Mitochondrial Fragmentation* , 2009, The Journal of Biological Chemistry.

[335]  Ole Isacson,et al.  Dynamic Changes in Presynaptic and Axonal Transport Proteins Combined with Striatal Neuroinflammation Precede Dopaminergic Neuronal Loss in a Rat Model of AAV α-Synucleinopathy , 2009, The Journal of Neuroscience.

[336]  S. Kerk,et al.  Dopamine auto‐oxidation aggravates non‐apoptotic cell death induced by over‐expression of human A53T mutant alpha‐synuclein in dopaminergic PC12 cells , 2009, Journal of neurochemistry.

[337]  M. Cookson,et al.  Leucine-rich repeat kinase 2 mutations and Parkinson’s disease: three questions , 2009, ASN neuro.

[338]  M. Goldenberg Medical management of Parkinson's disease. , 2008, P & T : a peer-reviewed journal for formulary management.

[339]  C. Singer,et al.  Is the G2019S LRRK2 mutation common in all southern European populations? , 2008, Journal of Clinical Neuroscience.

[340]  A. Stępień,et al.  Serum interleukin (IL-2, IL-10, IL-6, IL-4), TNFα, and INFγ concentrations are elevated in patients with atypical and idiopathic parkinsonism , 2008, Neuroscience Letters.

[341]  M. Farrer,et al.  Analysis of Lrrk2 R1628P as a risk factor for Parkinson's disease , 2008, Annals of neurology.

[342]  M. Farrer,et al.  Genomic investigation of α‐synuclein multiplication and parkinsonism , 2008, Annals of neurology.

[343]  C. Davie A review of Parkinson's disease. , 2008, British medical bulletin.

[344]  N. Quinn,et al.  Antineuronal antibodies in Parkinson's disease , 2008, Movement disorders : official journal of the Movement Disorder Society.

[345]  D. Eliezer,et al.  Structural effects of Parkinson's disease linked DJ‐1 mutations , 2008, Protein science : a publication of the Protein Society.

[346]  Daniela Berg,et al.  Biomarkers for the Early Detection of Parkinson’s and Alzheimer’s Disease , 2008, Neurodegenerative Diseases.

[347]  M. Parihar,et al.  Mitochondrial association of alpha-synuclein causes oxidative stress , 2008, Cellular and Molecular Life Sciences.

[348]  B. Cagniard,et al.  Unregulated Cytosolic Dopamine Causes Neurodegeneration Associated with Oxidative Stress in Mice , 2008, The Journal of Neuroscience.

[349]  Vladimir N. Uversky,et al.  Neuropathology, biochemistry, and biophysics of α‐synuclein aggregation , 2007 .

[350]  P. Calabresi,et al.  Lysosomal hydrolases in cerebrospinal fluid from subjects with Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[351]  P. Walter,et al.  Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.

[352]  Sarika Singh,et al.  Apoptotic neuronal death in Parkinson's disease: Involvement of nitric oxide , 2007, Brain Research Reviews.

[353]  J. Gorell,et al.  Whole-Body Lifetime Occupational Lead Exposure and Risk of Parkinson’s Disease , 2006, Environmental health perspectives.

[354]  David Oakes,et al.  Head injury and Parkinson's disease risk in twins , 2006, Annals of neurology.

[355]  K. Xia,et al.  Association of PINK1 and DJ-1 confers digenic inheritance of early-onset Parkinson's disease. , 2006, Human molecular genetics.

[356]  B. Jeon,et al.  Protective role of heat shock and heat shock protein 70 in lactacystin-induced cell death both in the rat substantia nigra and PC12 cells , 2006, Brain Research.

[357]  B. Zhivotovsky,et al.  Multiple pathways of cytochrome c release from mitochondria in apoptosis. , 2006, Biochimica et biophysica acta.

[358]  Andrew B West,et al.  Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[359]  B. Sonawane,et al.  Neurodegenerative Diseases: An Overview of Environmental Risk Factors , 2005, Environmental health perspectives.

[360]  Thomas Meitinger,et al.  Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology , 2004, Neuron.

[361]  A. Ludolph,et al.  Dopamine transporter: involvement in selective dopaminergic neurotoxicity and degeneration , 2004, Journal of Neural Transmission.

[362]  S. Leonard,et al.  Cadmium inhibits the electron transfer chain and induces reactive oxygen species. , 2004, Free radical biology & medicine.

[363]  J. Troncoso,et al.  S-Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function , 2004, Science.

[364]  R. Nussbaum,et al.  Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1 , 2004, Science.

[365]  P. Vandenabeele,et al.  Toxic proteins released from mitochondria in cell death , 2004, Oncogene.

[366]  Andre Parent,et al.  Presence of reactive microglia in monkey substantia nigra years after 1‐methyl‐4‐phenyl‐1,2,3,6‐tetrahydropyridine administration , 2003, Annals of neurology.

[367]  B. Oostra,et al.  DJ-1( PARK7), a novel gene for autosomal recessive, early onset parkinsonism , 2003, Neurological Sciences.

[368]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[369]  Lorene M Nelson,et al.  Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. , 2003, American journal of epidemiology.

[370]  G. Fiskum,et al.  Mitochondrial Mechanisms of Neural Cell Death and Neuroprotective Interventions in Parkinson's Disease , 2003, Annals of the New York Academy of Sciences.

[371]  Todd B. Sherer,et al.  Selective microglial activation in the rat rotenone model of Parkinson's disease , 2003, Neuroscience Letters.

[372]  G. Escames,et al.  Synergistic effects of melatonin and deprenyl against MPTP-induced mitochondrial damage and DA depletion , 2003, Neurobiology of Aging.

[373]  H. Braak,et al.  Staging of brain pathology related to sporadic Parkinson’s disease , 2003, Neurobiology of Aging.

[374]  Lloyd A Greene,et al.  Endoplasmic Reticulum Stress and the Unfolded Protein Response in Cellular Models of Parkinson's Disease , 2002, The Journal of Neuroscience.

[375]  Patrizia Rizzu,et al.  Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism , 2002, Science.

[376]  Patrik Brundin,et al.  Impaired dopamine storage resulting from alpha-synuclein mutations may contribute to the pathogenesis of Parkinson's disease. , 2002, Human molecular genetics.

[377]  M. Beal,et al.  Caspase-9 Activation Results in Downstream Caspase-8 Activation and Bid Cleavage in 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Parkinson's Disease , 2001, The Journal of Neuroscience.

[378]  Nikki J. Holbrook,et al.  Oxidants, oxidative stress and the biology of ageing , 2000, Nature.

[379]  M. Hengartner The biochemistry of apoptosis , 2000, Nature.

[380]  P. Krammer,et al.  The CD95 (APO-1/Fas) and the TRAIL (APO-2L) apoptosis systems. , 2000, Experimental cell research.

[381]  E. Hirsch,et al.  Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[382]  D. Nicholson,et al.  Caspase structure, proteolytic substrates, and function during apoptotic cell death , 1999, Cell Death and Differentiation.

[383]  J. Gorell,et al.  Occupational Metal Exposures and the Risk of Parkinson’s Disease , 1999, Neuroepidemiology.

[384]  C. Benoist,et al.  Mice lacking all conventional MHC class II genes. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[385]  N. Thornberry Caspases: key mediators of apoptosis. , 1998, Chemistry & biology.

[386]  S. Minoshima,et al.  Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism , 1998, Nature.

[387]  Robert L. Nussbaum,et al.  Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .

[388]  K. Marder,et al.  Risk of Parkinson's disease among first-degree relatives , 1996, Neurology.

[389]  Peter Riederer,et al.  Interleukin-1β and interleukin-6 are elevated in the cerebrospinal fluid of Alzheimer's and de novo Parkinson's disease patients , 1995, Neuroscience Letters.

[390]  S. Korsmeyer,et al.  Role of BCL-2 in the survival and function of developing and mature sympathetic neurons , 1995, Neuron.

[391]  Minoru Harada,et al.  Tumor necrosis factor-α (TNF-α) increases both in the brain and in the cerebrospinal fluid from parkinsonian patients , 1994, Neuroscience Letters.

[392]  P. Mcgeer,et al.  Microglial response to 6-hydroxydopamine-induced substantia nigra lesions , 1989, Brain Research.

[393]  OUP accepted manuscript , 2022, Brain.

[394]  D. Dickson Neuropathology of Parkinson disease. , 2018, Parkinsonism & related disorders.

[395]  M. Islam,et al.  G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain , 2018, Human molecular genetics.

[396]  W. Voos,et al.  Mitochondrial quality control by the Pink1/Parkin system , 2016, Cell and Tissue Research.

[397]  Christine Klein,et al.  Genetics of Parkinson's disease. , 2012, Cold Spring Harbor perspectives in medicine.

[398]  P. Heutink,et al.  Loss of function of DJ-1 triggered by Parkinson's disease-associated mutation is due to proteolytic resistance to caspase-6 , 2010, Cell Death and Differentiation.

[399]  P. Jenner Oxidative stress and Parkinson's disease. , 2007, Handbook of clinical neurology.

[400]  P. Kolatkar,et al.  The LRRK2 Gly2385Arg variant is associated with Parkinson’s disease: genetic and functional evidence , 2006, Human Genetics.

[401]  H. Lipp,et al.  Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease. , 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

[402]  H. Ichinose,et al.  Caspase activities and tumor necrosis factor receptor R1 (p55) level are elevated in the substantia nigra from Parkinsonian brain , 2000, Journal of Neural Transmission.

[403]  E. Zamrini,et al.  Apoptotic-like changes in Lewy-body-associated disorders and normal aging in substantia nigral neurons. , 1997, The American journal of pathology.